Consumer health tech · Preventive blood testing
Lucis
A Paris-based subscription that turns a blood draw at a partner lab into an AI-read dashboard of biomarkers, pitched as “Function Health for Europe.” Founded in 2025, it has raised about $28 million in eight months and is expanding across the continent.
A tableau of numbers instead of a PDF
The pitch is simple. A member pays a subscription, books a blood draw at a certified partner lab such as Eurofins, Randox, Cerba or Synlab, and gets back a dashboard instead of the usual multi-page printout. The panel covers, depending on which company materials you read, somewhere between 110 and more than 180 biomarkers across metabolic, hormonal, cardiovascular, inflammatory and nutritional systems. A medical team reviews the results, and an AI layer flags what is out of range and turns it into a plan across nutrition, supplements, movement, sleep and mental health.
One reviewer who paid for the service said the dashboard gave him “143 biomarqueurs analysés, un tableau de bord qui m’a sorti un âge biologique de 28 ans pour 34 au compteur.” The company’s own Y Combinator listing frames the ambition more bluntly: help people “live 100 healthy years from a simple blood test.”
The gap it says it is filling
Lucis’s framing leans on a World Health Organisation figure: its June 2025 European report attributes 1.8 million avoidable deaths a year in the WHO European Region to non-communicable disease, at a cost of $514 billion, and argues 60 percent could be prevented through risk-factor reduction. Lucis says the people who currently get comprehensive preventive blood work mostly do it through private longevity clinics charging well over €50,000 a year, out of reach for almost everyone.
The category is crowded. In the US, Function Health, Superpower and Forward sell a similar promise. In Europe, Lucis competes most directly with the Paris clinic Zoî, which charges around €990 to €3,590 a year for a clinic-heavy, less frequent check-up with more biomarkers per visit. Lucis’s bet is volume at a lower price: two draws a year at roughly €490, against Zoï’s single annual visit.
Three co-founders, a rebrand and a departure
Lucis was founded by Maxime Berthelot, Baptiste Debever and Max Corentin Guérois. Public filings trace the entity further back than the company’s own “founded 2025” line: it was first registered on April 30, 2024, in Tours under the name Maxes Company, with Guérois as president and Berthelot as director general. Before it carried the Lucis brand, a company database listed the same team’s project as Zero Health.
Roles shifted in August 2025: Berthelot became president, Guérois became director general, and Debever was added as a second director general. The company re-registered in Paris that October. A registry filing dated April 24, 2026, a few weeks before the Series A announcement, records Guérois departing as director general. Coverage of the Series A round is split: some outlets still list three founders, while EU-Startups and Vestbee describe Lucis as founded by “Maxime Berthelot and Baptiste Debever” only.
From Paris pilot to four countries in a year
The company says it worked with 500 people in Paris in its first four months. By its December 2025 seed announcement, it reported 3,000 customers, more than 500,000 clinical tests and over 400 partner labs across France, the UK, Ireland and Portugal. Five months later, at the Series A, it reported more than 10,000 users, over one million biomarker tests, a team of 20, and plans to add Spain, Germany and Italy by the end of 2026.
The seed round, $8.5 million led by General Catalyst with Y Combinator, Kima Ventures, Motier Ventures, Circle.Co and North South Ventures, closed in December 2025. Four months later Lucis raised a $20 million Series A led by Singular, with General Catalyst and Y Combinator returning alongside angels including Resilience’s Céline Lazorthes, Manu Lecomte and backers of the running app Runna.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Corporate registration | LUCIS SAS, SIREN 927 853 952, registered with the Paris commercial court since October 8, 2025. The entity originated as Maxes Company, registered in Tours on April 30, 2024, with a starting capital of €1,000. Its denomination changed to LUCIS in filings dated March and April 2026. Registered capital as of the most recent filing is a nominal €1,123.20, which does not reflect the roughly $28 million raised; French SAS structures typically hold invested capital as share premium rather than registered capital, and no annual accounts were yet public as of this writing. | Public record |
| Registered activity code | NAF/APE code 58.29C, “édition de logiciels applicatifs” (application software publishing). The registration does not classify Lucis as a medical laboratory; its partner labs carry that status separately. | Public record |
| Funding rounds | $8.5 million seed (December 2025) and $20 million Series A (May 2026), both reported by multiple independent outlets with named lead investors and amounts. No SEC Form D was found under either “Lucis” or “Maxes Company” on EDGAR as of September 25, 2026, consistent with a French entity raising largely from non-US-registered vehicles. | Independent |
| Biomarker count | Company materials cite “more than 180 biomarkers” in December 2025 coverage and “more than 110 biomarkers” in May 2026 coverage of the same product. A third-party reviewer counted 143 results on his dashboard in mid-2026. | Differs across dates |
| Outcomes data | Lucis says that among users completing a six-month follow-up, 75 percent improved at least three biomarkers without medication, more than 80 percent chose to retest, and 99.9 percent of first-time users had at least one biomarker outside the optimal range. These figures are company-supplied and unaudited. | Company-stated |
| Peer-reviewed evidence | No PubMed record for Lucis was found. The “biological age” concept it reports rests on a published phenotypic-age methodology from a 2018 PLoS Medicine paper by Liu and colleagues, but Lucis’s own scoring algorithm is proprietary and unpublished, per an independent reviewer. | Not found |
| Founding team | A registry filing dated April 24, 2026, records co-founder Max Guérois departing as director general. Press coverage of the Series A published weeks later is inconsistent on whether he remains a co-founder. | Differs from later coverage |
Read plainly: the commercial story, growing users, expanding countries, two funding rounds in four months, is well documented by independent press and the French corporate registry. The clinical story rests almost entirely on the company’s own figures. Lucis does not run its own lab and has not published outcomes data, so the biomarker-count discrepancy and the unaudited retention numbers are the main open questions.
What to watch
- Whether Lucis publishes its outcomes data anywhere independently reviewable.
- Confirmation of Max Guérois’s status after the April 2026 filing showing his departure as director general.
- Whether the promised expansion into Spain, Germany and Italy lands by end of 2026.
- Lucis’s first published annual accounts, which would show real revenue against reported volumes.
In their words
“If you're tired of being in the dark about your health, not knowing where you stand or what to do next, Lucis is built for you.”
From Lucis’s Y Combinator launch post, 2025 · Company
“Our mission is to empower individuals to take ownership of their health by giving them a clear view of key indicators before symptoms even appear, and providing practical guidance to improve their well-being, without replacing physicians.”
Maxime Berthelot, CEO and co-founder, Tech Funding News, Dec 16, 2025 · Company
“We've seen the devastating impact of late-stage diagnosis first-hand. The science is already there; what's missing is a system designed to act before symptoms appear.”
Maxime Berthelot, CEO and co-founder, EU-Startups, May 26, 2026 · Company
“Europe's preventive health category will be won by platforms that unite clinical credibility with AI at scale.”
Jeremy Uzan, co-founder and general partner, Singular, quoted in TNW, May 26, 2026 · Investor
“J'ai fait le test : 143 biomarqueurs analysés, un tableau de bord qui m'a sorti un âge biologique de 28 ans pour 34 au compteur.”
Charly Aourir, independent reviewer, Charly Aourir blog, Jul 22, 2026 · Independent
“Lucis makes it incredibly easy to get actionable insights from your blood work and health data.”
Customer review, Trustpilot, March 2026, collected via Versus.care · Customer review
Related companies
Sources
- Public recordSociété LUCIS (927853952): registration, BODACC filings and registered activity
- Public recordLucis SAS, Paris, Siren 927853952
- Public recordSEC EDGAR full text search and company search for “Lucis” and “Maxes Company,” Form D
- CompanyLucis: Function Health for Europe, company profile and launch post
- CompanyLucis raises $20M to make preventive health the standard across Europe
- IndependentParis preventive-health startup Lucis raises $20M Series A four months after seed
- IndependentYC-backed French preventive health platform Lucis raises €17.3 million Series A led by Singular
- IndependentLucis lands $20M Series A to expand its AI-driven preventive health platform across Europe
- IndependentFrench preventive healthcare startup Lucis raises €7.2 million from General Catalyst, Y Combinator, others
- IndependentFrench startup Lucis raises $8.5M to expand preventive healthcare across Europe
- IndependentYC-backed Lucis bags $8.5M to turn blood tests into Europe's daily health dashboard
- IndependentLucis lève 7,2 M€ pour devenir la Function Health européenne
- IndependentLucis (private company), formerly Zero Health
- IndependentLucis vs Zoï: quel bilan choisir en 2026
- IndependentLucis: mon avis complet sur le bilan sanguin préventif
- IndependentLucis: j'ai testé le test sanguin dont tout Paris parle
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
